Atlas Trials

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Clinical trial NCT02053376 · COMPLETED

Trial details

NCT number
NCT02053376
Sponsor
Nathan Bahary, MD
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Biliary Tract Carcinoma
Start date
2014-01-01
Primary completion
2018-01-07
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.